期刊文献+

辐照后基因修饰自然杀伤细胞的特征及对卵巢癌细胞杀伤活性的研究 被引量:1

Characterization of irradiated gene modified NK cells and cytotoxic activity against ovarian tumor cell
下载PDF
导出
摘要 目的探讨800cGy辐照后人白细胞介素15基因修饰的自然杀伤细胞(NKG-IL15)表面分子特征及其对卵巢癌细胞的杀伤活性。方法收集NKG-IL15细胞,800cGy进行辐照,100cGy/分,流式法检测辐照前后NKG-IL15细胞表型;利用51cr释放法检测辐照前后NKG-IL15细胞对靶细胞的杀伤活性,同时3H掺入法检测照射后细胞的增殖能力。结果 800cGy辐照前后NKG-IL15细胞表型均为CD56强阳性,CD19和CD3为阴性;对卵巢癌HO-8910细胞杀伤结果显示,0、800cGy组杀伤率分别在70.0%~23.7%、69.4%~22.6%之间,杀伤无明显差别;800cGy照射后NKG-IL15细胞24h增殖能力为0。结论 800cGy辐照后的NKG-IL15细胞具有人自然杀伤细胞的特征,无增殖能力,对人卵巢癌细胞HO-8910有较高的杀伤活性,可成为卵巢癌过继性免疫治疗的方法 。 Objective To study the characterization of the irradiated interleukin-15 gene-modified human natural killer cells (NKG-IL15) at 800cGy,and cytotoxic activity against human ovarian tumor cells in vitro.Methods NKG-IL15 cells were harvested and irradiated at dose of 800cGy,100cGy/min;the surface phenotype of the irradiated NKG-IL15 cells were acquired by FACS;The cytotoxic activity of NKG-IL15 (800cGy) against target cells was measured by a standard 4-h 51Cr release assay;and the proliferation of irradiated NKG-IL15 cells was quantified using a standard 3H-thymidine incorporation assay.Results The phenotype of NKG-IL15 and irradiated cells at doses 800cGy were all expressed CD56+ and CD3-CD19-;the cytotoxic of NKG-IL15 was approximately at 69.4%-22.6% for ovarian tumor cell line HO-8910 at 800cGy and it was 70.0%-23.7% at 0 cGy.By the 3H-thymidine incorporation analysis,it was found that there was no cell proliferation after the irradiation by 800cGy.Conclusion NKG-IL15 cells which were irradiated at 800cGy are highly cytotoxic to human ovarian tumor cells and have no proliferation in vitro.Thus,irradiated NKG-IL15 cells may be a potentially novel therapy for human ovarian carcinoma.
出处 《中国临床保健杂志》 CAS 2010年第3期278-280,共3页 Chinese Journal of Clinical Healthcare
基金 安徽省科技攻关课题(08010302101)
关键词 卵巢肿瘤 杀伤细胞 天然 免疫表型分型 细胞增殖 Ovarian neoplasms Killer cells natural Immunophenotyping Cell proliferation
  • 相关文献

参考文献12

二级参考文献57

  • 1方平,里晓红,沙群,张琨龄,周青.EB病毒在鼻咽癌发生中的作用[J].临床耳鼻咽喉科杂志,2004,18(10):599-601. 被引量:3
  • 2Yan Y,Steinherz P,Klingemann HG,et al.Antileukemia activity of a natural killer cell line against human leukemia[J].Clin Cancer Res,1998,4:2859-2868
  • 3Klingemann HG,Wong E,Maki G.A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood[J]. Biol Blood Marrow Transplant,1996,2:68-75
  • 4Tam YK,Maki G,Miyagawa B,et al.Characterization of genetically altered,interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy[J].Hum Gene Ther,1999,10:1359-1373
  • 5Tam YK,Miyagawa B,Ho VC,et al.Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92[J].J Hematother,1999,8:281-290
  • 6Ochsenbein AF,Sierro S,Odermatt B,et al.Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction[J].Nature,2001,411:1058-1064
  • 7Basse P,Herberman RB,Nannmark U,et al.Accumulation of adoptively transferred adherent,lymphokine-activated killer cells in murine metastases[J].J Exp Med,1991,174:479-488
  • 8Crowley NJ,Vervaert CE,Seigler HF.Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T cells[J].Cancer Res,1992,52:394-399
  • 9Rosenberg SA,Lotze MT,Yang JC,et al.Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer[J].J Natl Cancer Inst,1993,85:622-632
  • 10Rosenberg SA,Yannelli JR,Yang JC,et al.Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2[J].J Natl Cancer Inst,1994,86:1159-1166

共引文献21

同被引文献22

  • 1陈纲,凌斌,祝怀平,赵卫东,王群华,张红雁,吴爱东,魏海明,田志刚.自然杀伤细胞系NK-92治疗卵巢癌的体外及动物实验研究[J].中华妇产科杂志,2005,40(7):476-479. 被引量:10
  • 2Satthapong D, Tangjitgamol S, Manusirivithaya S, et al. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer [J]. J Med Assoc Thai, 2007, 90 (3) : 411-419.
  • 3Terme M, Ullrich E, Delahaye NF, et al. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies [Jl. Nat Immunol, 2008, 9(5) : 486-494.
  • 4Malmberg K J, Bryceson YT, Carlsten M, et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy [ J ]. Cancer Immunol Immunother, 2008, 57 (10) : 1541-1552.
  • 5Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo [J]. J Exp ned, 2009, 206(1): 25-34.
  • 6Jiang W, Zhang J, Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL [J]. Cytotherapy, 2008, 10(3) : 265-274.
  • 7Zhang J, Sun R, Wei H, et al. Characterization of interleukin-15 gene-modified human natural killer ceils: Implications for adoptive cellular immunotherapy [ J ]. Haematologica, 2004, 89 (3): 338- 347.
  • 8Malmberg K J, Levitsky V, Norell H, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/ NKG2A-dependent mechanism [ J]. J Clin Invest, 2002, 110 (10) : 1515-1523.
  • 9Gong JH, Maki G, Klingemann HC. Characterization of a human cell line ( NK-92 ) with phenotypical and functional characteristics of activated natural killer cells [J]. Leukemia, 1994, 8 (4) : 652-658.
  • 10Friberg DD, Bryant JL, Whiteside TL. Measurements of natural killer (NK) activity and NK-cell quantification [ J ]. Methods, 1996, 9(2) : 316-326.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部